AI Article Synopsis
- Limited research exists on the indirect costs related to skin and soft tissue infections (SSTIs) in children, prompting a systematic review to fill this gap.
- Thirteen studies were included in the review, highlighting indirect costs from various countries, with significant losses reported for infections like varicella-zoster virus and community-associated methicillin-resistant Staphylococcus aureus.
- The findings reveal that indirect costs associated with SSTIs are substantial but often overlooked, emphasizing the need for more research to accurately assess the economic impact of these infections.
Article Abstract
Background: There are limited data in the literature on the indirect costs associated with skin and soft tissue infections (SSTIs) in the pediatric population. This study aimed to conduct a systematic review of the indirect costs associated with SSTIs in children.
Methods: The search was conducted in PubMed, SCOPUS, and Web of Science up to January 2020. Thirteen search strategies were designed combining MeSH terms and free terms. SSTIs were defined as bacterial or viral infections, dermatomycoses, and parasitic infestations. Only primary studies were included. All analyzed costs were converted to 2020 Euros.
Results: Thirteen of the identified publications presented indirect costs of SSTIs in children and were conducted in Argentina, Australia, Brazil, Hungary, New Zealand, Poland, Spain, Taiwan, and the USA. Nine studies described indirect costs associated with infection of Varicella-zoster virus: lost workdays by outpatient caregivers ranged from 0.27 to 7.8, and up to 6.14 if caring for inpatients; total productivity losses ranged from €1.16 to €257.46 per patient. Three studies reported indirect costs associated with acute bacterial SSTIs (community-associated methicillin-resistant Staphylococcus aureus) in children: total productivity losses ranged from €1,814.39 to €8,224.06 per patient, based on impetigo, cellulitis, and folliculitis. One study of parasitic infestations (Pediculus humanus capitis) reported total indirect costs per patient of €68.57 (formal care) plus €21.41 due to time lost by parents in purchasing treatment.
Conclusions: The economic burden of SSTIs is highly relevant but underestimated due to the lack of studies reporting indirect costs. Further cost studies will allow a better understanding of the magnitude of the financial burden of the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665520 | PMC |
| http://dx.doi.org/10.1186/s12913-021-07189-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Financial Impact of Ehlers-Danlos Syndromes on Patients in the United States in 2022.
Mayo Clin Proc Innov Qual Outcomes
February 2025
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.
Objective: To determine the financial impact of Ehlers-Danlos syndromes (EDS) on patients in the United States by examining the medical expenses incurred by patients.
Patients And Methods: We used a convenience sample approach and disseminated a self-reported survey questionnaire to individuals with EDS via patient advocacy organizations and support groups across the country, social media, and health professionals from April 1, 2023, to December 31, 2023. The survey focused on the out-of-pocket medical expenses incurred by patients.
Clinical evaluation of long-read sequencing-based episignature detection in developmental disorders.
Genome Med
January 2025
Laboratory of Cytogenetics and Genome Research, Centre for Human Genetics, KU Leuven, Leuven, 3000, Belgium.
Background: A subset of developmental disorders (DD) is characterized by disease-specific genome-wide methylation changes. These episignatures inform on the underlying pathogenic mechanisms and can be used to assess the pathogenicity of genomic variants as well as confirm clinical diagnoses. Currently, the detection of these episignature requires the use of indirect methylation profiling methodologies.
View Article and Find Full Text PDFBackground: There are 6.7 million people living with dementia in the United States, and this number is projected to increase as the population ages. The cost of informal care makes up a large proportion of the societal costs of dementia due to the significant care needs associated with the condition.
View Article and Find Full Text PDFTotal Healthcare Costs across the Alzheimer’s Disease Continuum in the United States (US).
Alzheimers Dement
December 2024
Alzheimer’s Disease & Brain Health, Eisai Inc., Nutley, NJ, USA
Background: This study describes the total healthcare costs integrating direct, indirect, and intangible or emotional cost components across the severity stages of Alzheimer’s disease (AD) in US.
Method: Utilizing Health and Retirement Study (HRS) data (1994‐2018), a bi‐annual US national survey of older adults, we assessed out‐of‐pocket and indirect costs, including unpaid caregiving services, missed workdays, and early retirement. HRS, analyzed with sampling weights, provided a representative US national sample.
Assessment of Financial Toxicity in an ADRC Cohort: a Pilot Study.
Alzheimers Dement
December 2024
College of Public Health, University of Kentucky, Lexington, KY, USA
Background: Alzheimer’s disease and related dementias (ADRD) are associated with substantial direct healthcare costs, including specialist care, medication, and indirect costs related to loss of productivity and informal caregiving. The economic burden of ADRD on families and caregivers often threatens the financial security of entire households. The consequences of this financial burden are linked to a worsened quality of life and treatment compliance, rapid disease progression, and lower survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!